BOOST Pharma has appointed Hans Schambye as its new chief executive officer, taking over from his previous role on the company’s board of directors.

The leadership transition comes as the clinical-stage biopharmaceutical company prepares for Phase 3 development of its lead candidate, BT‑101, a potential disease-modifying treatment for osteogenesis imperfecta (OI), also known as Brittle Bone Disease.

BT‑101 is an off-the-shelf cell therapy targeting the underlying causes of OI, a rare genetic disorder characterised by fragile bones, skeletal deformities, hearing impairment, and respiratory complications. In a Phase 1/2 trial, BOOST Pharma reported a reduction in fractures of over 70% in the first year and approximately 78% in the second year, with most patients experiencing no fractures in year two. The company is planning Phase 3 trials in children with severe forms of OI (Type 3 and 4).

Ingelise Saunders, Chair of BOOST Pharma, said: “Hans’ transition to CEO comes at a pivotal time for the company. With his deep scientific insight and seasoned operational leadership, Hans is uniquely positioned to accelerate clinical development through its next phase and drive long‑term value‑creation for BOOST.”

Hans Schambye commented: “BOOST Pharma brings together world-class science, a truly exceptional team, and a late-stage candidate with the potential to transform the lives of children with osteogenesis imperfecta. The strength of the BT‑101 data to date, combined with its path toward Phase 3, is incredibly compelling. I am deeply motivated by what this company has already achieved and excited to help accelerate clinical development to address a clear unmet need.”

BOOST Pharma develops first-in-class off-the-shelf cell therapies for rare pediatric skeletal diseases. Osteogenesis imperfecta affects an estimated 1 in 15,000 people globally and currently has only supportive treatment options.